WO2016194884A1 - Method for inactivating airborne microorganisms - Google Patents
Method for inactivating airborne microorganisms Download PDFInfo
- Publication number
- WO2016194884A1 WO2016194884A1 PCT/JP2016/065949 JP2016065949W WO2016194884A1 WO 2016194884 A1 WO2016194884 A1 WO 2016194884A1 JP 2016065949 W JP2016065949 W JP 2016065949W WO 2016194884 A1 WO2016194884 A1 WO 2016194884A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- chlorine dioxide
- chlorite
- light
- present
- concentration
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 136
- 244000005700 microbiome Species 0.000 title claims abstract description 41
- 230000000415 inactivating effect Effects 0.000 title claims abstract description 11
- OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 claims abstract description 604
- 239000004155 Chlorine dioxide Substances 0.000 claims abstract description 302
- 235000019398 chlorine dioxide Nutrition 0.000 claims abstract description 302
- 229910001919 chlorite Inorganic materials 0.000 claims abstract description 95
- 229910052619 chlorite group Inorganic materials 0.000 claims abstract description 95
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 claims abstract description 92
- 239000003054 catalyst Substances 0.000 claims abstract description 60
- 239000007787 solid Substances 0.000 claims abstract description 45
- 239000011148 porous material Substances 0.000 claims abstract description 42
- 229910052751 metal Inorganic materials 0.000 claims abstract description 31
- 239000002184 metal Substances 0.000 claims abstract description 31
- 229910044991 metal oxide Inorganic materials 0.000 claims abstract description 29
- 150000004706 metal oxides Chemical class 0.000 claims abstract description 29
- 239000003814 drug Substances 0.000 claims description 175
- 229940079593 drug Drugs 0.000 claims description 79
- 241000700605 Viruses Species 0.000 claims description 61
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 59
- 239000003795 chemical substances by application Substances 0.000 claims description 39
- 229960005196 titanium dioxide Drugs 0.000 claims description 33
- 239000004408 titanium dioxide Substances 0.000 claims description 28
- 230000001678 irradiating effect Effects 0.000 claims description 27
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 239000003513 alkali Substances 0.000 claims description 15
- 238000007667 floating Methods 0.000 claims description 15
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 12
- 241001465754 Metazoa Species 0.000 claims description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 12
- 241000894006 Bacteria Species 0.000 claims description 10
- 239000004113 Sepiolite Substances 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 9
- 229910052624 sepiolite Inorganic materials 0.000 claims description 9
- 235000019355 sepiolite Nutrition 0.000 claims description 9
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 8
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 claims description 7
- 229960002218 sodium chlorite Drugs 0.000 claims description 7
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 6
- 229910052625 palygorskite Inorganic materials 0.000 claims description 5
- VISKNDGJUCDNMS-UHFFFAOYSA-M potassium;chlorite Chemical compound [K+].[O-]Cl=O VISKNDGJUCDNMS-UHFFFAOYSA-M 0.000 claims description 5
- 239000010936 titanium Substances 0.000 claims description 5
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 claims description 5
- 239000005909 Kieselgur Substances 0.000 claims description 4
- 229910021543 Nickel dioxide Inorganic materials 0.000 claims description 4
- 229910021536 Zeolite Inorganic materials 0.000 claims description 4
- QXIKMJLSPJFYOI-UHFFFAOYSA-L calcium;dichlorite Chemical compound [Ca+2].[O-]Cl=O.[O-]Cl=O QXIKMJLSPJFYOI-UHFFFAOYSA-L 0.000 claims description 4
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 claims description 4
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 claims description 4
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 claims description 4
- 229910052808 lithium carbonate Inorganic materials 0.000 claims description 4
- KAGBQTDQNWOCND-UHFFFAOYSA-M lithium;chlorite Chemical compound [Li+].[O-]Cl=O KAGBQTDQNWOCND-UHFFFAOYSA-M 0.000 claims description 4
- 229910052901 montmorillonite Inorganic materials 0.000 claims description 4
- 229940073644 nickel Drugs 0.000 claims description 4
- 229910003445 palladium oxide Inorganic materials 0.000 claims description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 4
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 claims description 4
- 229910001952 rubidium oxide Inorganic materials 0.000 claims description 4
- 239000000741 silica gel Substances 0.000 claims description 4
- 229910002027 silica gel Inorganic materials 0.000 claims description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 4
- 239000010457 zeolite Substances 0.000 claims description 4
- WOHVONCNVLIHKY-UHFFFAOYSA-L [Ba+2].[O-]Cl=O.[O-]Cl=O Chemical compound [Ba+2].[O-]Cl=O.[O-]Cl=O WOHVONCNVLIHKY-UHFFFAOYSA-L 0.000 claims description 3
- SHFGJEQAOUMGJM-UHFFFAOYSA-N dialuminum dipotassium disodium dioxosilane iron(3+) oxocalcium oxomagnesium oxygen(2-) Chemical compound [O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Na+].[Na+].[Al+3].[Al+3].[K+].[K+].[Fe+3].[Fe+3].O=[Mg].O=[Ca].O=[Si]=O SHFGJEQAOUMGJM-UHFFFAOYSA-N 0.000 claims description 2
- 239000010451 perlite Substances 0.000 claims description 2
- 235000019362 perlite Nutrition 0.000 claims description 2
- 239000013043 chemical agent Substances 0.000 abstract 5
- 238000003860 storage Methods 0.000 description 39
- 238000002474 experimental method Methods 0.000 description 32
- 238000012360 testing method Methods 0.000 description 30
- 239000000243 solution Substances 0.000 description 26
- 239000000463 material Substances 0.000 description 24
- 239000000126 substance Substances 0.000 description 18
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 15
- 239000002245 particle Substances 0.000 description 15
- 239000002609 medium Substances 0.000 description 14
- 230000008859 change Effects 0.000 description 13
- 229920001817 Agar Polymers 0.000 description 9
- 239000008272 agar Substances 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000006199 nebulizer Substances 0.000 description 8
- 239000011347 resin Substances 0.000 description 7
- 229920005989 resin Polymers 0.000 description 7
- 241000712461 unidentified influenza virus Species 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 5
- 235000019345 sodium thiosulphate Nutrition 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 241000714201 Feline calicivirus Species 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- -1 alkali metal chlorite Chemical class 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 230000009849 deactivation Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 238000004255 ion exchange chromatography Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 3
- 241001139947 Mida Species 0.000 description 3
- 241000191963 Staphylococcus epidermidis Species 0.000 description 3
- 238000004378 air conditioning Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000007664 blowing Methods 0.000 description 3
- 238000007599 discharging Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 3
- 239000004745 nonwoven fabric Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- LHEJDBBHZGISGW-UHFFFAOYSA-N 5-fluoro-3-(3-oxo-1h-2-benzofuran-1-yl)-1h-pyrimidine-2,4-dione Chemical compound O=C1C(F)=CNC(=O)N1C1C2=CC=CC=C2C(=O)O1 LHEJDBBHZGISGW-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 241000709687 Coxsackievirus Species 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241001263478 Norovirus Species 0.000 description 2
- 241001631646 Papillomaviridae Species 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 229910001562 pearlite Inorganic materials 0.000 description 2
- CPRMKOQKXYSDML-UHFFFAOYSA-M rubidium hydroxide Chemical compound [OH-].[Rb+] CPRMKOQKXYSDML-UHFFFAOYSA-M 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- MFGOFGRYDNHJTA-UHFFFAOYSA-N 2-amino-1-(2-fluorophenyl)ethanol Chemical compound NCC(O)C1=CC=CC=C1F MFGOFGRYDNHJTA-UHFFFAOYSA-N 0.000 description 1
- 241000589291 Acinetobacter Species 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241000588923 Citrobacter Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 241001466953 Echovirus Species 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000544 Gore-Tex Polymers 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 241000701460 JC polyomavirus Species 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 241000712902 Lassa mammarenavirus Species 0.000 description 1
- 241000555676 Malassezia Species 0.000 description 1
- 241001115401 Marburgvirus Species 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 241000150350 Peribunyaviridae Species 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000702247 Reoviridae Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000369757 Sapovirus Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241001529934 Simian T-lymphotropic virus 3 Species 0.000 description 1
- 241000713311 Simian immunodeficiency virus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000893966 Trichophyton verrucosum Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241000607272 Vibrio parahaemolyticus Species 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- ISFLYIRWQDJPDR-UHFFFAOYSA-L barium chlorate Chemical compound [Ba+2].[O-]Cl(=O)=O.[O-]Cl(=O)=O ISFLYIRWQDJPDR-UHFFFAOYSA-L 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Inorganic materials [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 230000001877 deodorizing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000002289 effect on microbe Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 1
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 description 1
- NWAPVVCSZCCZCU-UHFFFAOYSA-L magnesium;dichlorite Chemical compound [Mg+2].[O-]Cl=O.[O-]Cl=O NWAPVVCSZCCZCU-UHFFFAOYSA-L 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 244000309711 non-enveloped viruses Species 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000006150 trypticase soy agar Substances 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
- A61L2/20—Gaseous substances, e.g. vapours
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/26—Accessories or devices or components used for biocidal treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L9/00—Disinfection, sterilisation or deodorisation of air
- A61L9/01—Deodorant compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L9/00—Disinfection, sterilisation or deodorisation of air
- A61L9/015—Disinfection, sterilisation or deodorisation of air using gaseous or vaporous substances, e.g. ozone
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J21/00—Catalysts comprising the elements, oxides, or hydroxides of magnesium, boron, aluminium, carbon, silicon, titanium, zirconium, or hafnium
- B01J21/16—Clays or other mineral silicates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J35/00—Catalysts, in general, characterised by their form or physical properties
-
- B01J35/30—
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B11/00—Oxides or oxyacids of halogens; Salts thereof
- C01B11/02—Oxides of chlorine
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B11/00—Oxides or oxyacids of halogens; Salts thereof
- C01B11/02—Oxides of chlorine
- C01B11/022—Chlorine dioxide (ClO2)
- C01B11/023—Preparation from chlorites or chlorates
- C01B11/024—Preparation from chlorites or chlorates from chlorites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
- A61L2202/10—Apparatus features
- A61L2202/11—Apparatus for generating biocidal substances, e.g. vaporisers, UV lamps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
- A61L2202/20—Targets to be treated
- A61L2202/25—Rooms in buildings, passenger compartments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2209/00—Aspects relating to disinfection, sterilisation or deodorisation of air
- A61L2209/20—Method-related aspects
- A61L2209/21—Use of chemical compounds for treating air or the like
Definitions
- the present invention relates to a method for inactivating suspended microorganisms in a space using low concentration chlorine dioxide gas.
- Chlorine dioxide gas is a safe gas for animal organisms at low concentrations (for example, 0.3 ppm or less), but even at such low concentrations, it has a deactivating effect on microorganisms such as bacteria, fungi, and viruses, It is known to have a deodorizing action and the like. Because of these characteristics, chlorine dioxide gas has attracted particular attention in applications such as deodorization, sterilization, virus removal, antifungal and antiseptic during environmental purification and food transportation.
- chlorine dioxide gas is safe for animal bodies at low concentrations and can be used for various purposes.
- a method for inactivating respiratory viruses and the like using low-concentration chlorine dioxide gas has been proposed (for example, Patent Document 1).
- Patent Document 1 a method for inactivating respiratory viruses and the like using low-concentration chlorine dioxide gas.
- Patent Document 1 since chlorine dioxide gas can be harmful to the animal's body at high concentrations and there is a danger of explosion, development of a method for stably generating chlorine dioxide gas has been studied for practical use. .
- Patent Document 2 a method of generating chlorine dioxide by irradiating a gel composition comprising chlorite and a water-absorbing resin with ultraviolet rays (for example, Patent Document 2), or a porous carrier containing chlorite and an alkali agent.
- Patent Document 3 A method of generating chlorine dioxide by using the stabilized chlorine dioxide impregnated and dried and bringing the stabilized chlorine dioxide agent into contact with air has been proposed (for example, Patent Document 3).
- the method of the present invention in one embodiment, is a method for inactivating suspended microorganisms in space, (1): (A) preparing a solid drug containing a porous material supporting chlorite and (B) a metal catalyst or a metal oxide catalyst; Here, the mass ratio of the chlorite and the metal catalyst or metal oxide catalyst in the solid drug is 1: 0.04 to 0.8; (2): irradiating the solid drug with visible light; and (3): A method comprising: supplying chlorine dioxide gas generated from the solid drug to a space where airborne microorganisms exist.
- the chlorine dioxide gas concentration in the space is 0.1 ppm to 0.3 ppm in the step (3)
- the chlorine dioxide gas is supplied into the space.
- the time is 0.5 minutes to 480 minutes.
- the method of the present invention is characterized in that the metal catalyst or metal oxide catalyst is selected from the group consisting of palladium, rubidium, nickel, titanium, and titanium dioxide.
- the porous material is selected from the group consisting of sepiolite, palygorskite, montmorillonite, silica gel, diatomaceous earth, zeolite, and pearlite, and the chlorite is chlorite. It is characterized by being selected from the group consisting of sodium acid, potassium chlorite, lithium chlorite, calcium chlorite, and barium chlorite.
- the “porous material carrying a chlorite and an alkali agent” is the same as that described above, wherein the chlorite and the alkali agent are simultaneously or sequentially converted into a porous material. It is obtained by impregnating and drying.
- the agent containing the solid chlorite is (A) a porous material supporting chlorite, and (B) a metal catalyst or metal oxidation. It is a chemical
- the chlorine dioxide generator used for the method of the present invention in one embodiment, at least one of the openings of the medicine container is present on a side surface of the medicine container, and is sent from the blower. The air is sent to the medicine at least partially through an opening existing on a side surface of the medicine storage section.
- the chlorine dioxide generator used in the method of the present invention is such that the relative humidity in the medicine container is maintained at 30 to 80% RH by the air sent from the blower.
- FIG. 13 shows a case where light is emitted from only two light sources (one side) when light is emitted from two light sources (both sides) in the chlorine dioxide generating unit according to an embodiment of the present invention. It is the figure explaining that light can be efficiently delivered to the chemical
- FIG. 14 shows a change in the amount of chlorine dioxide generated when the relative humidity in the medicine container is changed in the chlorine dioxide generation unit according to the embodiment of the present invention. In addition, in FIG. 14, the data at the time of irradiating light from only one light source part (one side) are shown.
- FIG. 15 shows changes over time in the amount of chlorine dioxide generated when the relative humidity in the medicine container is changed in the chlorine dioxide generation unit according to the embodiment of the present invention.
- FIG. 17 shows a schematic diagram of an experiment for inactivating suspended microorganisms in the space using the method of the present invention.
- the content of the metal catalyst or metal oxide catalyst exceeds 1 times the content of chlorite and when the content of metal catalyst or metal oxide catalyst is 0% of the content of chlorite In any case of less than .04 times, the amount of chlorine dioxide generated when irradiated with visible light can be reduced.
- the fact that the wavelength of light generated from the light source is substantially included in the range of the specific wavelength region can be confirmed by measuring the wavelength and energy of the light generated from the light source with a known measuring device.
- the relative humidity in the medicine container is 30 to 80% RH (preferably 40 to 70% RH, more preferably 40 by the air sent from the blower. To 60% RH).
- the amount of chlorine dioxide generated can be increased by adjusting the relative humidity in the medicine container within the above range.
- the ozone concentration decreased to about 43% from the ultraviolet region to the visible region.
- the chlorine dioxide concentration increased to about 213% from the ultraviolet region to the visible region.
- the amount of chlorine dioxide generated when the test drug is irradiated with visible light is such that the mass ratio of titanium dioxide to chlorite in the drug is 0 to about 0.001. It was shown that it increased as it increased to 3, and gradually decreased when the mass ratio of titanium dioxide to chlorite exceeded about 0.3. Furthermore, it was shown that when the mass ratio of titanium dioxide to chlorite in the composition exceeds about 1.0, the amount of chlorine dioxide generated is lower than when titanium dioxide is not mixed.
- FIG. 10 is a diagram showing the internal structure of the chlorine dioxide generator 40, which is an embodiment of the present invention.
- the chlorine dioxide generator 40 of this invention is equipped with the unit for a chlorine dioxide generation (LED chip mounting substrate 41 and chemical
- the chlorine dioxide generator further includes a blower fan 44 inside, and supplies air into the chlorine dioxide generation unit by driving the blower fan 44. By adjusting the driving of the blower fan 44, the relative humidity in the medicine container in the chlorine dioxide generating unit can be adjusted.
- Example 5 Examination of the relative humidity of the medicine container Using the chlorine dioxide generating unit shown in FIG. 9 and the chlorine dioxide generator shown in FIG. 10, chlorine dioxide is generated by the relative humidity in the medicine container. Changes in the amount were examined.
- Example 4 The same conditions as in Example 4 were used for measuring the drug stored in the drug storage unit, the visible light irradiation method, and the chlorine dioxide concentration.
- the relative humidity in the medicine container was adjusted by controlling the amount of air supplied to the medicine container (that is, the amount of water vapor supplied to the medicine) by driving the blower fan.
- 14 and 15 show the relationship between the relative humidity in the medicine container and the chlorine dioxide concentration in the chamber.
- FIG. 14 shows the average value of the chlorine dioxide concentration measured several times during the light irradiation of 0.5 to 2 hours and its standard deviation
- FIG. 15 shows the change over time of the chlorine dioxide concentration in the chamber. Show.
- Example 6 Examination of usefulness of intermittent irradiation Using the unit for generating chlorine dioxide shown in FIG. 9, the usefulness of intermittent irradiation of visible light in the present invention was examined.
- Chlorine dioxide gas concentration of 1 m 3 chamber was monitored by chlorine dioxide gas sensor.
- the concentration value of the chlorine dioxide gas sensor was corrected in comparison with the gas concentration value obtained by ion chromatography.
- the viable cell count was 4.1 ⁇ 10 3 CFU / 10L air in 90 minutes.
- the chlorine dioxide gas concentration in the chamber was an average of 0.05 ppmv, and the viable cell count was 3.4 ⁇ 10 2 CFU / at an exposure time of 90 minutes. It became 10L air, and was reduced by 1 log 10 or more (90% or more) with respect to the control (FIG. 25).
Abstract
Description
(1):(A)亜塩素酸塩を担持させた多孔質物質と(B)金属触媒または金属酸化物触媒とを含む、固形の薬剤を準備するステップ、
ここで、前記固形の薬剤における、前記亜塩素酸塩と前記金属触媒または金属酸化物触媒との質量比が、1:0.04~0.8である;
(2):前記固形の薬剤に、可視光を照射するステップ;および、
(3):前記固形の薬剤から発生する二酸化塩素ガスを、浮遊微生物の存在する空間へ供給するステップ;を含む、方法に関する。 That is, the method of the present invention, in one embodiment, is a method for inactivating suspended microorganisms in space,
(1): (A) preparing a solid drug containing a porous material supporting chlorite and (B) a metal catalyst or a metal oxide catalyst;
Here, the mass ratio of the chlorite and the metal catalyst or metal oxide catalyst in the solid drug is 1: 0.04 to 0.8;
(2): irradiating the solid drug with visible light; and
(3): A method comprising: supplying chlorine dioxide gas generated from the solid drug to a space where airborne microorganisms exist.
(1):下記の構成を備える二酸化塩素発生用ユニットを準備するステップ、
前記ユニットは、薬剤収納部、および、少なくとも2つの光源部を備え、
前記光源部は、実質的に可視領域の波長からなる光を発生させるためのものであり、
前記薬剤収納部には、固形の亜塩素酸塩を含む薬剤が収納されており、
前記薬剤収納部には、前記薬剤収納部の内部と外部をエアが移動できるように、1または複数の開口部が備えられており、
ここで、前記薬剤収納部の内部に存在する前記薬剤が、前記光源部から発生される前記光によって照射されることにより、二酸化塩素ガスが発生する;および、
(2):前記二酸化塩素発生用ユニットから発生する二酸化塩素ガスを、浮遊微生物の存在する空間へ供給するステップ;を含む、方法に関する。 In another embodiment, the method of the present invention is a method for inactivating suspended microorganisms in space, comprising:
(1): a step of preparing a unit for generating chlorine dioxide having the following configuration;
The unit includes a medicine container and at least two light sources.
The light source unit is for generating light having a wavelength in a visible region substantially,
In the medicine container, a medicine containing solid chlorite is housed,
The medicine container is provided with one or more openings so that air can move inside and outside the medicine container,
Here, chlorine dioxide gas is generated by irradiating the medicine existing inside the medicine storage part with the light generated from the light source part; and
(2): Supplying chlorine dioxide gas generated from the chlorine dioxide generating unit to a space where floating microorganisms are present.
(1):(A)亜塩素酸塩を担持させた多孔質物質と(B)金属触媒または金属酸化物触媒とを含む、固形の薬剤を準備するステップ、
ここで、前記固形の薬剤における、前記亜塩素酸塩と前記金属触媒または金属酸化物触媒との質量比が、1:0.04~0.8である;
(2):前記固形の薬剤に、可視光を照射するステップ;および、
(3):前記固形の薬剤から発生する二酸化塩素ガスを、浮遊微生物の存在する空間へ供給するステップ;を含む、方法を提供する。 In one embodiment, the method of the present invention is a method for inactivating suspended microorganisms in space, comprising:
(1): (A) preparing a solid drug containing a porous material supporting chlorite and (B) a metal catalyst or a metal oxide catalyst;
Here, the mass ratio of the chlorite and the metal catalyst or metal oxide catalyst in the solid drug is 1: 0.04 to 0.8;
(2): irradiating the solid drug with visible light; and
(3): supplying chlorine dioxide gas generated from the solid drug to a space where airborne microorganisms are present.
例えば浮遊ウイルス、浮遊細菌、浮遊真菌が挙げられる。浮遊ウイルスとしてはエンベロープのあるウイルスあるいはエンベロープのないウイルス、例えば、水痘・帯状疱疹ウイルス、インフルエンザウイルス(ヒト、鳥、豚など)、単純性疱疹ウイルス、アデノウイルス、エンテロウイルス、ライノウイルス、ヒトパピローマウイルス(ヒト乳頭種ウイルス)、ボックスウイルス、コクサッキーウイルス、単純ヘルペスウイルス、サイトメガロウイルス、EBウイルス、アデノウイルス、パピローマウイルス、JCウイルス、パルボウイルス、B型肝炎ウイルス、C型肝炎ウイルス、ラッサウイルス、ネコカリシウイルス、ノロウイルス、サポウイルス、コロナウイルス、SARSウイルス、風疹ウイルス、ムンプスウイルス、麻疹ウイルス、RSウイルス、ポリオウイルス、コクサッキーウイルス、エコーウイルス、マールブルグウイルス、エボラウイルス、黄熱病ウイルス、ブンヤウイルス科のウイルス、狂犬病ウイルス、レオウイルス科のウイルス、ロタウイルス、ヒト免疫不全ウイルス、ヒトTリンパ好性ウイルス、サル免疫不全ウイルス、STLVなどが挙げられる。また、浮遊細菌としてはグラム陽性菌あるいはグラム陰性菌、例えば、黄色ブドウ球菌、表皮ブドウ球菌、緑膿菌、大腸菌、連鎖球菌、淋菌、梅毒菌、髄膜炎菌、結核菌、抗酸菌、クレブシエラ(肺炎桿菌)、サルモネラ菌、ボツリヌス菌、プロテウス、百日咳菌、セラチア菌、腸炎ビブリオ菌、シトロバクター、アシネトバクター、カンピロバクター、エンテロバクター、マイコプラズマ、クラミジア、クロストリジウムなどが挙げられる。さらに、浮遊真菌としては、例えば、アスペルギルス、白癬菌、マラセチア菌、カンジダなどが挙げられる。 The floating microorganism in the method of the present invention broadly means a microorganism that can float in the space,
Examples include airborne viruses, airborne bacteria, and airborne fungi. Airborne viruses include enveloped or non-enveloped viruses such as varicella / zoster virus, influenza virus (human, bird, swine, etc.), herpes simplex virus, adenovirus, enterovirus, rhinovirus, human papillomavirus (human) Papillomavirus), box virus, coxsackie virus, herpes simplex virus, cytomegalovirus, EB virus, adenovirus, papilloma virus, JC virus, parvovirus, hepatitis B virus, hepatitis C virus, lassa virus, feline calicivirus, Norovirus, Sapovirus, Coronavirus, SARS virus, Rubella virus, Mumps virus, Measles virus, RS virus, Poliovirus, Coxsackie virus , Echovirus, Marburg virus, Ebola virus, yellow fever virus, Bunyaviridae virus, rabies virus, reoviridae virus, rotavirus, human immunodeficiency virus, human T lymphophilic virus, simian immunodeficiency virus, STLV Etc. In addition, as floating bacteria, Gram-positive bacteria or Gram-negative bacteria, such as Staphylococcus aureus, Staphylococcus epidermidis, Pseudomonas aeruginosa, Escherichia coli, Streptococcus, Neisseria gonorrhoeae, syphilis, meningococcus, tuberculosis, acid-fast bacilli, Examples include Klebsiella (Klebsiella pneumoniae), Salmonella, Clostridium botulinum, Proteus, Bordetella pertussis, Serratia, Vibrio parahaemolyticus, Citrobacter, Acinetobacter, Campylobacter, Enterobacter, Mycoplasma, Chlamydia, Clostridium and the like. Furthermore, examples of the floating fungi include Aspergillus, ringworm, Malassezia, and Candida.
(1):下記の構成を備える二酸化塩素発生用ユニットを準備するステップ、
前記ユニットは、薬剤収納部、および、少なくとも2つの光源部を備え、
前記光源部は、実質的に可視領域の波長からなる光を発生させるためのものであり、
前記薬剤収納部には、固形の亜塩素酸塩を含む薬剤が収納されており、
前記薬剤収納部には、前記薬剤収納部の内部と外部をエアが移動できるように、1または複数の開口部が備えられており、
ここで、前記薬剤収納部の内部に存在する前記薬剤が、前記光源部から発生される前記光によって照射されることにより、二酸化塩素ガスが発生する;および、
(2):前記二酸化塩素発生用ユニットから発生する二酸化塩素ガスを、浮遊微生物の存在する空間へ供給するステップ;を含む、方法を提供する。 In another embodiment, the method of the present invention is a method for inactivating suspended microorganisms in space, comprising:
(1): a step of preparing a unit for generating chlorine dioxide having the following configuration;
The unit includes a medicine container and at least two light sources.
The light source unit is for generating light having a wavelength in a visible region substantially,
In the medicine container, a medicine containing solid chlorite is housed,
The medicine container is provided with one or more openings so that air can move inside and outside the medicine container,
Here, chlorine dioxide gas is generated by irradiating the medicine existing inside the medicine storage part with the light generated from the light source part; and
(2): providing a chlorine dioxide gas generated from the chlorine dioxide generating unit to a space where floating microorganisms are present.
In the following, the present invention will be described in more detail with reference to examples. However, the invention can be embodied in various ways and should not be construed as limited to the embodiments set forth herein.
本実施例においては、図1および図2に記載の二酸化塩素発生ユニットおよび二酸化塩素発生装置を用いて試験を行った。 Example 1: Change in chlorine dioxide generation amount depending on the wavelength of light to be irradiated In this example, a test was performed using the chlorine dioxide generation unit and the chlorine dioxide generator shown in FIGS. 1 and 2.
本実施例において用いるサンプル1では、粒状の二酸化チタン(チタンを焼成処理して調製したもの)を用いた以外は、実施例1と同様の方法で薬剤を調製した。本実施例で用いるサンプル2およびサンプル3では、実施例1と同様の方法で薬剤を調製した。 Example 2: Change in chlorine dioxide generation amount depending on
10wt%亜塩素酸ナトリウム水溶液70gを100gのセピオライトに噴霧吸着させ乾燥させた後、さらに10wt%水酸化ナトリウム水溶液20gを噴霧吸着させて乾燥させた。これに、粉状の二酸化チタンを、量を変化させて混合し、本実施例に用いる試験用薬剤とした。試験用薬剤への可視光の照射は、実施例1と同じ二酸化塩素発生装置および照射方法にて行い、二酸化塩素濃度の測定も、実施例1と同様に行った。 Example 3: Examination of the content ratio of chlorite and titanium dioxide in the drug After 70 g of 10 wt% sodium chlorite aqueous solution was spray-adsorbed on 100 g of sepiolite and dried, another 20 g of 10 wt% sodium hydroxide aqueous solution was sprayed. Adsorbed and dried. To this, powdery titanium dioxide was mixed in various amounts to obtain a test agent used in this example. The test drug was irradiated with visible light using the same chlorine dioxide generator and irradiation method as in Example 1, and the chlorine dioxide concentration was also measured in the same manner as in Example 1.
本発明における、光源部のサンドイッチ構造の有効性についての試験を行った。本実施例においては、図9に記載の二酸化塩素発生用ユニット、および、図10に記載の二酸化塩素発生装置を用いて実験を行った。 Example 4 Examination of Sandwich Structure of Light Source Unit The effectiveness of the sandwich structure of the light source unit in the present invention was tested. In this example, an experiment was performed using the unit for generating chlorine dioxide shown in FIG. 9 and the chlorine dioxide generator shown in FIG.
図9に記載の二酸化塩素発生用ユニット、および、図10に記載の二酸化塩素発生装置を用いて、薬剤収納部内の相対湿度による、二酸化塩素発生量の変化について検討した。 Example 5: Examination of the relative humidity of the medicine container Using the chlorine dioxide generating unit shown in FIG. 9 and the chlorine dioxide generator shown in FIG. 10, chlorine dioxide is generated by the relative humidity in the medicine container. Changes in the amount were examined.
図9に記載の二酸化塩素発生用ユニットを用いて、本発明における、可視光の間欠照射の有用性について検討を行った。 Example 6: Examination of usefulness of intermittent irradiation Using the unit for generating chlorine dioxide shown in FIG. 9, the usefulness of intermittent irradiation of visible light in the present invention was examined.
(2)照射開始2分間は光を照射し続け、照射開始2分以降は、20秒光を照射(LEDをON)し、80秒光の照射を停止(LEDをOFF)するというサイクルを繰り返した。
(3)照射開始2分間は光を照射し続け、照射開始2分以降は、30秒光を照射(LEDをON)し、80秒光の照射を停止(LEDをOFF)するというサイクルを繰り返した。
本試験の結果を図16に示す。なお、図16のグラフにおける「相対ClO2ガス濃度」は、照射開始2分後の二酸化塩素濃度を1とした場合の、それぞれの時間における二酸化塩素濃度の相対値を表す。 (1) The light is continuously irradiated for 2 minutes from the start of irradiation, and after 2 minutes from the start of irradiation, the light is irradiated for 10 seconds (LED is turned on) and the light irradiation is stopped for 80 seconds (the LED is turned off). It was.
(2) Repeated the cycle of irradiating light for 2 minutes from the start of irradiation, irradiating light for 20 seconds (LED is turned on) and stopping light irradiation for 80 seconds (LED is turned off) after 2 minutes from the start of irradiation. It was.
(3) The light irradiation is continued for 2 minutes after the start of irradiation, and after 2 minutes from the start of irradiation, the light is irradiated for 30 seconds (LED is turned on) and the light irradiation is stopped for 80 seconds (the LED is turned off). It was.
The results of this test are shown in FIG. The “relative ClO 2 gas concentration” in the graph of FIG. 16 represents the relative value of the chlorine dioxide concentration at each time when the
(試験ウイルス)
Escherichia coli phage phiX174 (NBRC 103405)
(宿主菌)
Escherichia coli (NBRC 13898)
(ガス発生装置)
本発明の二酸化塩素発生用ユニットを組み込んだ二酸化塩素発生装置
(実験器具)
1m3チャンバー(特注品)
14ml Tube(352059,FALCON)
エーゼ(INO-001,IWAKI)
AC FAN(MU1225S-11,ORIX)
ネブライザー(NE-C29,OMRON)
排気用ヘパフィルター(排気用超小型特殊フィルタ,OSHITARI LABORATORY)
インピンジャー(Biosampler,5ml,SKC)
(実験機器)
振とう培養機(AT12R,THOMAS)
二酸化塩素ガスセンサー(ClO2 1000ppb,INTERSCAN)
二酸化塩素ガスセンサー(Midas GAS Detector,ClO2 MIDAS-E-BR2,Honeywell)
パーティクルカウンター(KC-52,RION)
粒子除去用エアーフィルター(MAC-11FR-UL,日本エアーテック)
分光光度計(V-560,JASCO)
恒温槽(MCO-175,SANYO)
エアーポンプ(SPP-25GA,TECHNO TAKATSUKI)
温湿度計(PC-5000TRH,SATO)
イオンクロマトグラフ(HIC-20ASP,SHIMADZU)
(実験材料)
NB培地(234000,Nutrient Broth,Difco)
702培地(ポリペプトン10g,酵母エキス 2g,硫酸マグネシウム7水和物 1g,蒸留水 1L)
普通寒天培地(E-MP21,栄研化学)
寒天(Bacto Agar 214010,BD) 1. Experimental materials and equipment (test virus)
Escherichia coli phage phiX174 (NBRC 103405)
(Host fungus)
Escherichia coli (NBRC 13898)
(Gas generator)
Chlorine dioxide generator (laboratory equipment) incorporating the unit for generating chlorine dioxide of the present invention
1m 3 chamber (custom product)
14ml Tube (352059, FALCON)
AZE (INO-001, IWAKI)
AC FAN (MU1225S-11, ORIX)
Nebulizer (NE-C29, OMRON)
Hepa filter for exhaust (ultra-small special filter for exhaust, OSHIARI LABORATORY)
Impinger (Biosampler, 5 ml, SKC)
(Experimental equipment)
Shaking incubator (AT12R, THOMAS)
Chlorine dioxide gas sensor (ClO 2 1000ppb, INTERSCAN)
Chlorine dioxide gas sensor (Midas GAS Detector, ClO 2 MIDAS-E-BR2, Honeywell)
Particle counter (KC-52, RION)
Air filter for particle removal (MAC-11FR-UL, Nippon Airtech)
Spectrophotometer (V-560, JASCO)
Thermostatic bath (MCO-175, SANYO)
Air pump (SPP-25GA, TECHNO TAKASUKI)
Thermo-hygrometer (PC-5000TRH, SATO)
Ion chromatograph (HIC-20ASP, SHIMADZU)
(Experimental material)
NB medium (234000, Nutrient Broth, Difco)
702 medium (polypeptone 10 g, yeast extract 2 g, magnesium sulfate heptahydrate 1 g, distilled water 1 L)
Ordinary agar medium (E-MP21, Eiken Chemical)
Agar (Bacto Agar 21410, BD)
(試験ウイルス液の調整)
前培養した保存菌株Escherichia coliを5mlのNB+0.5%NaCl液体培地に接種し、30℃、200rpmで6時間振とう培養した。培養後のEscherichia coli(約1×109cells/ml)100μlとphage phiX174(約1×105PFU/ml)in NB+0.5%NaCl液体培地500μlを混合し、37℃,5分間インキュベートした。その混合液に3mlのNB+0.5%NaCl培地(0.6%agar)を加えて混合し、普通寒天培地に重層後、37℃で18時間培養した。トップアガーに2mlのNB+0.5%NaCl液体培地を加えて回収し、0.22μmのフィルターでろ過したものを分注し、-85℃で保管した。その一部を常法に従ってプラークアッセイを行い約1×1010PFU/mlのウイルス液を得た。試験前に-85℃で凍結させたウイルスを融解させた後、蒸留水で10倍希釈したものを試験ウイルス液(噴霧液;1×108~9PFU/ml)とした。 2. Experimental method (adjustment of test virus solution)
The pre-cultured stock strain Escherichia coli was inoculated into 5 ml of NB + 0.5% NaCl liquid medium and cultured with shaking at 30 ° C. and 200 rpm for 6 hours. After incubation, Escherichia coli (about 1 × 10 9 cells / ml) (100 μl) and phase phiX174 (about 1 × 10 5 PFU / ml) in NB + 0.5% NaCl liquid medium (500 μl) were mixed and incubated at 37 ° C. for 5 minutes. 3 ml of NB + 0.5% NaCl medium (0.6% agar) was added to the mixture and mixed, and the mixture was overlaid on a normal agar medium and cultured at 37 ° C. for 18 hours. The top agar was recovered by adding 2 ml of NB + 0.5% NaCl liquid medium, which was filtered through a 0.22 μm filter, and stored at −85 ° C. A part thereof was subjected to a plaque assay according to a conventional method to obtain a virus solution of about 1 × 10 10 PFU / ml. A virus frozen at −85 ° C. before the test was thawed and diluted 10-fold with distilled water to obtain a test virus solution (spray solution; 1 × 10 8 to 9 PFU / ml).
本実施例における実験の概略を図17に示した。
1m3チャンバーの中央部に本発明の二酸化塩素発生装置を設置し、タイマーにより装置のon、offを制御しながら稼働させることにより、チャンバー内の二酸化塩素ガス濃度が0.05、0.1、又は、0.3ppmvとなるように調節した。ガス濃度が安定したチャンバー内にネブライザーを用いて、phiX174ファージウイルス(約1×108~9PFU/ml)を0.2ml/minの速度で5分間噴霧した。二酸化塩素濃度を約0.05ppmvとしたチャンバーにおいては、0、30、60、75、90分後に、二酸化塩素濃度を約0.1ppmvとしたチャンバーにおいては、0、15、30、45、60分後に、二酸化塩素濃度を約0.3ppmvとしたチャンバーにおいては、0、5、10、15、30分後に、インピンジャーを用いてウイルスを含む空気を回収した。回収したウイルスをプラークアッセイし、空気10L中のウイルス数を求め評価した。同様に,二酸化塩素発生装置のLEDを常にOFFとしたものをコントロールとした。 (experimental method)
An outline of the experiment in this example is shown in FIG.
1 m 3 established the chlorine dioxide generator of the present invention in the central portion of the chamber, on the device by the timer, by operating at a controlled off, the chlorine dioxide gas concentration in the chamber 0.05, 0.1, Or it adjusted so that it might become 0.3 ppmv. Gas concentration using a nebulizer to a stable chamber, phiX174 phage virus (about 1 × 10 8 ~ 9 PFU / ml) was sprayed for 5 minutes at a rate of 0.2 ml / min. In a chamber with a chlorine dioxide concentration of about 0.05 ppmv, after 0, 30, 60, 75, 90 minutes, in a chamber with a chlorine dioxide concentration of about 0.1 ppmv, 0, 15, 30, 45, 60 minutes. Later, in a chamber having a chlorine dioxide concentration of about 0.3 ppmv, after 0, 5, 10, 15, and 30 minutes, air containing virus was collected using an impinger. The collected virus was subjected to a plaque assay, and the number of viruses in 10 L of air was determined and evaluated. Similarly, a control in which the LED of the chlorine dioxide generator was always turned off was used as a control.
1m3チャンバー内の二酸化塩素ガス濃度は、二酸化塩素ガスセンサーによりモニタリングされた。二酸化塩素ガスセンサーの濃度値はイオンクロマトグラフ法により求めたガス濃度値と比較して補正された。 (Monitoring of chlorine dioxide gas concentration)
Chlorine dioxide gas concentration of 1 m 3 chamber was monitored by chlorine dioxide gas sensor. The concentration value of the chlorine dioxide gas sensor was corrected in comparison with the gas concentration value obtained by ion chromatography.
二酸化塩素濃度を約0.05ppmvとしたチャンバーの空気中におけるウイルス力価の変化を図18に、二酸化塩素濃度を約0.1ppmvとしたチャンバーの空気中におけるウイルス力価の変化を図19に、二酸化塩素濃度を約0.3ppmvとしたチャンバーの空気中におけるウイルス力価の変化を図20に示した。なお、図18に示す実験は、温度:23.1±0.2℃、相対湿度:57.2±0.4%の条件下で実施され、図19に示す実験は、温度:22.9±0.2℃、相対湿度:59.4±0.7%の条件下で実施され、図20に示す実験は、温度:23.1±0.3℃、相対湿度:59.3±0.5%の条件下で実施された。 3. Results Figure 18 shows the change in virus titer in the air of the chamber with a chlorine dioxide concentration of about 0.05 ppmv, and Figure 19 shows the change in virus titer in the air of the chamber with a chlorine dioxide concentration of about 0.1 ppmv. FIG. 20 shows the change in virus titer in the air in the chamber where the chlorine dioxide concentration was about 0.3 ppmv. The experiment shown in FIG. 18 was performed under the conditions of temperature: 23.1 ± 0.2 ° C. and relative humidity: 57.2 ± 0.4%, and the experiment shown in FIG. The experiment shown in FIG. 20 was conducted at a temperature of 23.1 ± 0.3 ° C. and a relative humidity of 59.3 ± 0. Performed under 5% condition.
Blachereらによる病院救急部の浮遊インフルエンザウイルス数を測定した報告がある(Blachere,M.F.,et.al.Measurement of airborne influenza virus in a hospital emergency department. Clin. Infect. Dis. 48, 438-440 (2009))。当文献には、National Institute for Occupational Safty and Health 2-stage cyclone aerosol samplerを用いて、3.5L/minで4時間、室内の空気を吸引して、空中に存在するインフルエンザウイルス数を測定した結果、待合室で16,278ウイルス粒子数を検出したことが記載されている。この結果から空間中に含まれていたウイルス濃度を算出すると、約1.9×102ウイルス粒子数/10Lとなる。すなわち、インフルエンザウイルスが多く存在する可能性が高い空間(例えば、インフルエンザウイルス患者が多く来院する、病院)において、空間中のインフルエンザウイルス濃度は、約1.9×102ウイルス粒子数/10L程度であると考えられる。 4). Discussion There is a report of the number of airborne influenza viruses in hospital emergency departments measured by Blachere et al. (Blachere, MF, et al. Measurement of airborne virus in a hospital epidemic. -440 (2009)). This document describes the results of measuring the number of influenza viruses in the air by aspirating indoor air at 3.5 L / min for 4 hours using the National Institute for Occupational Safety and Health 2-stage cyclone aerosol sampler. It is described that the number of 16,278 virus particles was detected in the waiting room. From this result, the virus concentration contained in the space is calculated to be about 1.9 × 10 2 virus particles / 10 L. That is, in a space where there is a high possibility that many influenza viruses exist (for example, hospitals where many influenza virus patients visit), the concentration of influenza virus in the space is about 1.9 × 10 2 virus particles / 10 L. It is believed that there is.
実施例7と同様のものを用いた。 1. Experimental materials and experimental equipment The same materials as in Example 7 were used.
試験ウイルス液の調整および二酸化塩素ガス濃度のモニタリングについては、実施例7と同様の方法を用いて行った。 2. Experimental Method Test Virus solution preparation and chlorine dioxide gas concentration monitoring were performed using the same method as in Example 7.
1m3チャンバーの中央部に本発明の二酸化塩素発生装置を設置し、タイマーにより装置のon、offを制御しながら稼働させることにより、チャンバー内の二酸化塩素ガス濃度が約0.3ppmvとなるように調節した。ガス濃度が安定したチャンバー内にネブライザーを用いて、phiX174ファージウイルス(約1×108~9PFU/ml)を0.2ml/minの速度で1分間噴霧した。ウイルスの噴霧から0、2、4、6分後にインピンジャーを用いてウイルスを含む空気を回収した。回収したウイルスをプラークアッセイし、空気10L中のウイルス数を求め評価した。同様に、二酸化塩素発生装置のLEDを常にOFFとしたものをコントロールとした。 (experimental method)
1 m 3 established the chlorine dioxide generator of the present invention in the central portion of the chamber, on the device by the timer, by operating at a controlled off, so that the chlorine dioxide gas concentration in the chamber is about 0.3ppmv Adjusted. Using a nebulizer, a phiX174 phage virus (about 1 × 10 8 to 9 PFU / ml) was sprayed at a rate of 0.2 ml / min for 1 minute in a chamber with a stable gas concentration. At 0, 2, 4, and 6 minutes after virus spraying, air containing virus was collected using an impinger. The collected virus was subjected to a plaque assay, and the number of viruses in 10 L of air was determined and evaluated. Similarly, a control in which the LED of the chlorine dioxide generator was always turned OFF was used.
本発明の二酸化塩素発生装置のLEDを常にOFFとしたコントロール実験の場合、1m3チャンバー内の空気10L中のウイルス力価は、2分で9.2×104PFU/10L、4分で8.5×104PFU/10L、6分で6.3×104PFU/10Lであった(図21)。 3. Results In the control experiment in which the LED of the chlorine dioxide generator of the present invention was always turned off, the virus titer in 10 L of air in the 1 m 3 chamber was 9.2 × 10 4 PFU / 10 L in 2 minutes and 4 minutes. It was 8.5 × 10 4 PFU / 10L and 6.3 × 10 4 PFU / 10L in 6 minutes (FIG. 21).
(試験ウイルス)
Feline Calicivirus(FCV,F9,ATCC VR-782);ノロウイルスの代替として使用
(ホスト細胞)
Crandell Reese feline kidney cells(CRFK,ATCC CCL-94)
(ガス発生装置)
本発明の二酸化塩素発生用ユニットを組み込んだ二酸化塩素発生装置
(実験器具)
100Lステンレス製チャンバー(特注品)
96穴マイクロプレート(353072,FALCON)
96穴ディープウエルプレート(BM6030,BM Bio)
Reagent Reservoirs/Tip-Tub(022265806,eppendorf)
AC FAN(MU825S-13N, ORIX)
ネブライザー(NE-C29, OMRON)
排気用ヘパフィルター(排気用超小型特殊フィルタ,OSHITARI LABORATORY)
インピンジャー(Biosampler,5ml,SKC)
Centriprep 50K限外ろ過膜(4310,Merck Millipore)
Amicon Ultra 50K 限外ろ過膜(UFC505024,Merck Millipore)
(実験機器)
振とう培養機(AT12R,THOMAS)
二酸化塩素ガスセンサー(Midas GAS Detector,ClO2 MIDAS-E-BR2,Honeywell)
データロガー(GL220,GRAPHTEC)
オムロンタイマー(H5CX,OMRON)
パーティクルカウンター(KC-52,RION)
CO2インキュベーター(MCO-175AICUVH,PANASONIC)
エアーポンプ(SPP-25GA,TECHNO TAKATSUKI)
温湿度計(TR-72wf,T&D)
イオンクロマトグラフ(HIC-20ASP,SHIMADZU)
湿度調整器(ADPAC-N1000-AH,ADTEC)
清浄空気供給装置(ADFRESH-1000,ADTEC)
温湿度ユニット(TH-RS12,ADTEC)
温湿度計(TR-72wf,T&D CORPORATION)
流量計(RK3300,KOFLOC)
イオンクロマトグラフィー(ICS-3000,DIONEX)
位相差顕微鏡(CK30,OLYMPUS)
(実験材料)
Dulbecco’s Modified Eagle’s Medium-high glucose(D-MEM,D5796,SIGMA)
Dulbecco’s Phosphate Buffered Saline(D8537,SIGMA)
0.25% Trypsin Solution(35555-54,Nacalai tesque)
Fetal Bovine Serum(FBS,30-2020,ATCC)
EDTA Disodium Salt 2% Solution in PBS Saline(2820549,MP)
(インピンジャー用ウイルス回収液(中和液))
1mMチオ硫酸ナトリウム溶液*含有 0.1% FBS D-MEM(抗生物質添加)の5mLをインピンジャー用のウイルス回収液とした。
*1mMチオ硫酸ナトリウム溶液は0.3ppmvの二酸化塩素ガスを12.5L通気させた時に問題なく中和できる濃度である。 1. Experimental materials and equipment (test virus)
Feline Calicivirus (FCV, F9, ATCC VR-782); used as an alternative to norovirus (host cells)
Crandell Reese felt kidney cells (CRFK, ATCC CCL-94)
(Gas generator)
Chlorine dioxide generator (laboratory equipment) incorporating the chlorine dioxide generator unit of the present invention
100L stainless steel chamber (custom product)
96-well microplate (353072, FALCON)
96-well deep well plate (BM6030, BM Bio)
Reagent Researchers / Tip-Tub (022265806, eppendorf)
AC FAN (MU825S-13N, ORIX)
Nebulizer (NE-C29, OMRON)
Hepa filter for exhaust (ultra-small special filter for exhaust, OSHIARI LABORATORY)
Impinger (Biosampler, 5 ml, SKC)
Centriprep 50K ultrafiltration membrane (4310, Merck Millipore)
Amicon Ultra 50K Ultrafiltration Membrane (UFC505024, Merck Millipore)
(Experimental equipment)
Shaking incubator (AT12R, THOMAS)
Chlorine dioxide gas sensor (Midas GAS Detector, ClO 2 MIDAS-E-BR2, Honeywell)
Data logger (GL220, GRAPHTEC)
OMRON Timer (H5CX, OMRON)
Particle counter (KC-52, RION)
CO 2 incubator (MCO-175AICUVH, PANASONIC)
Air pump (SPP-25GA, TECHNO TAKASUKI)
Thermo-hygrometer (TR-72wf, T & D)
Ion chromatograph (HIC-20ASP, SHIMADZU)
Humidity adjuster (ADPAC-N1000-AH, ADTEC)
Clean air supply device (ADFRES-1000, ADTEC)
Temperature / humidity unit (TH-RS12, ADTEC)
Thermo-hygrometer (TR-72wf, T & D CORPORATION)
Flow meter (RK3300, KOFLOC)
Ion chromatography (ICS-3000, DIONEX)
Phase contrast microscope (CK30, OLYMPUS)
(Experimental material)
Dulbecco's Modified Eagle's Medium-high glucose (D-MEM, D5796, SIGMA)
Dulbecco's Phosphate Buffered Saline (D8537, SIGMA)
0.25% Trypsin Solution (35555-54, Nacalai quest)
Fetal Bovine Serum (FBS, 30-2020, ATCC)
(Impinger virus recovery solution (neutralization solution))
5 mL of 0.1% FBS D-MEM (containing antibiotics) containing 1 mM sodium thiosulfate solution * was used as a virus recovery solution for Impinger.
* 1 mM sodium thiosulfate solution has a concentration that can be neutralized without problems when 12.5 L of 0.3 ppmv chlorine dioxide gas is passed through.
(ウイルス噴霧液の調整)
-80℃に冷凍保存していたFeline calicivirus (108.5 TCID50/50μL)を0.1% FBS溶液で10倍希釈しものをウイルス噴霧液とした(107.5TCID50/50μL)。 2. Experimental method (adjustment of virus spray)
-80 ° C. Feline were cryopreserved calicivirus a (10 8.5 TCID 50 / 50μL) what was diluted 10-fold with 0.1% FBS solution was virus spray (10 7.5 TCID 50 / 50μL) .
100Lのステンレス製チャンバーの中央部に本発明の二酸化塩素発生装置を設置し、タイマーにより装置のon,offを制御しながら稼働させて、チャンバー内の二酸化塩素ガス濃度が0.3ppmvとなるように調節した(図22)。ガス濃度が安定したチャンバー内にネブライザーを用いて、ネコカリシウイルス(107.5TCID50/50μL)を0.2ml/minの速度で1分間噴霧し、0,2.5,5,10分後にインピンジャーによりウイルスを回収した。5mLのウイルス回収液は2種類の限外ろ過膜により約50μLにまで濃縮された(空気12.5L中のウイルス)。このウイルス濃縮液よりタイターを測定し、空気10L中のウイルス感染価を求め評価した。また、コントロールとして、二酸化塩素発生装置中の二酸化塩素発生用ユニットにおいて、薬剤収納部に薬剤を入れずに上記と同様の実験を行った。 (experimental method)
Install the chlorine dioxide generator of the present invention in the center of a 100 L stainless steel chamber and operate it while controlling the on / off of the device with a timer so that the chlorine dioxide gas concentration in the chamber becomes 0.3 ppmv. Adjustment (Figure 22). Using a nebulizer, a feline calicivirus (10 7.5 TCID 50/50 μL) is sprayed at a rate of 0.2 ml / min for 1 minute in a chamber with a stable gas concentration, and then 0, 2.5, 5, 10 minutes. Later, the virus was recovered by Impinger. 5 mL of virus recovery solution was concentrated to about 50 μL by two types of ultrafiltration membranes (virus in 12.5 L of air). The titer was measured from this virus concentrate, and the virus infectivity in 10 L of air was determined and evaluated. As a control, an experiment similar to the above was performed in the chlorine dioxide generating unit in the chlorine dioxide generator without putting the drug in the drug storage unit.
100Lチャンバー内の二酸化塩素ガス濃度は二酸化塩素ガスセンサーによりモニタリングされた。二酸化塩素ガスセンサーの濃度値はイオンクロマトグラフ法により求めたガス濃度値と比較して補正された。 (Chlorine dioxide gas concentration)
The chlorine dioxide gas concentration in the 100 L chamber was monitored by a chlorine dioxide gas sensor. The concentration value of the chlorine dioxide gas sensor was corrected in comparison with the gas concentration value obtained by ion chromatography.
装置において薬剤を使用しないコントロール実験の場合、10分後のウイルスタイターは、104.0TCID50/10L airであった。一方、本発明の装置に薬剤を入れて実験を行った場合、チャンバー内の二酸化塩素ガス濃度は平均0.25ppmv(min;0.22ppmv,max;0.32ppmv)であり、10分後のウイルスタイターは、100.6TCID50/10L airとなり、コントロールに対して2log10以上(99%以上)低減した(図23)。 3. Experimental results In a control experiment in which no drug was used in the apparatus, the virus titer after 10 minutes was 10 4.0 TCID 50 / 10L air. On the other hand, when the experiment was conducted by putting the drug into the apparatus of the present invention, the chlorine dioxide gas concentration in the chamber was 0.25 ppmv (min; 0.22 ppmv, max; 0.32 ppmv) on average, and the virus after 10 minutes The titer was 10 0.6 TCID 50 / 10L air, which was 2 log 10 or more (99% or more) lower than the control (FIG. 23).
(試験微生物)
Staphylococcus epidermidis(NBRC 12993)
(ガス発生装置)
本発明の二酸化塩素発生用ユニットを組み込んだ二酸化塩素発生装置
(実験器具)
1m3チャンバー(特注品)
エーゼ(INO-001,IWAKI)
96穴ディープウエルプレート(BM6030,BM Bio)
Reagent Reservoirs/Tip-Tub(022265806,eppendorf)
AC FAN(MU1225S-11,ORIX)
ネブライザー(NE-C29,OMRON)
排気用ヘパフィルター(排気用超小型特殊フィルタ,OSHITARI LABORATORY)
インピンジャー(Biosampler,5ml,SKC)
(実験機器)
二酸化塩素ガスセンサー(Midas GAS Detector,ClO2 MIDAS-E-BR2,Honeywell)
パーティクルカウンター(KC-52,RION)
粒子除去用エアーフィルター(MAC-11FR-UL,日本エアーテック)
分光光度計(V-560,JASCO)
恒温槽(MCO-175,SANYO)
エアーポンプ(SPP-25GA,TECHNO TAKATSUKI)
温湿度計(PC-5000TRH,SATO)
流量計(RK3300,KOFLOC)
イオンクロマトグラフ(HIC-20ASP, SHIMADZU)
(実験材料)
SCD培地(393-00185,日水製薬)
SCD寒天培地(396-00175,日水製薬)
普通寒天培地(E-MP21,栄研化学)
トリプチケースソイ寒天培地(236950,BD Biosciences)
0.1mol/l チオ硫酸ナトリウム溶液(191-03625,wako)
(インピンジャー用浮遊菌回収液(中和液))
1mMチオ硫酸ナトリウム溶液*含有SCD培地5mLをインピンジャー用の浮遊菌回収液とした。
*1mMチオ硫酸ナトリウム溶液は0.05ppmvの二酸化塩素ガスを12.5L通気させた時に問題なく中和できる濃度である。 1. Experimental materials and equipment (test microorganisms)
Staphylococcus epidermidis (NBRC 12993)
(Gas generator)
Chlorine dioxide generator (laboratory equipment) incorporating the unit for generating chlorine dioxide of the present invention
1m 3 chamber (custom product)
AZE (INO-001, IWAKI)
96-well deep well plate (BM6030, BM Bio)
Reagent Researchers / Tip-Tub (022265806, eppendorf)
AC FAN (MU1225S-11, ORIX)
Nebulizer (NE-C29, OMRON)
Hepa filter for exhaust (ultra-small special filter for exhaust, OSHIARI LABORATORY)
Impinger (Biosampler, 5 ml, SKC)
(Experimental equipment)
Chlorine dioxide gas sensor (Midas GAS Detector, ClO 2 MIDAS-E-BR2, Honeywell)
Particle counter (KC-52, RION)
Air filter for particle removal (MAC-11FR-UL, Nippon Airtech)
Spectrophotometer (V-560, JASCO)
Thermostatic bath (MCO-175, SANYO)
Air pump (SPP-25GA, TECHNO TAKASUKI)
Thermo-hygrometer (PC-5000TRH, SATO)
Flow meter (RK3300, KOFLOC)
Ion chromatograph (HIC-20ASP, SHIMADZU)
(Experimental material)
SCD medium (393-00185, Nissui Pharmaceutical)
SCD agar medium (396-00175, Nissui Pharmaceutical)
Ordinary agar medium (E-MP21, Eiken Chemical)
Trypticase Soy Agar (236950, BD Biosciences)
0.1 mol / l sodium thiosulfate solution (191-03625, wako)
(Floating bacteria collection solution for impinger (neutralization solution))
5 mL of 1 mM sodium thiosulfate solution * -containing SCD medium was used as a suspension recovery solution for Impinger.
* 1 mM sodium thiosulfate solution has a concentration that can be neutralized without problems when 12.5 L of 0.05 ppmv chlorine dioxide gas is passed through.
(試験菌液の調整)
前培養した保存菌株Staphylococcus epidermidisを普通寒天培地に植菌し、30℃で培養した。得られた菌体を滅菌精製水にて希釈したものを試験菌液(噴霧液;1×108~9 CFU/ml)とした。 2. Experimental method (adjustment of test bacterial solution)
The pre-cultured stock strain Staphylococcus epidermidis was inoculated on a normal agar medium and cultured at 30 ° C. A solution obtained by diluting the obtained bacterial cells with sterilized purified water was used as a test bacterial solution (spray solution; 1 × 10 8 to 9 CFU / ml).
1m3チャンバーの中央部に本発明の二酸化塩素発生装置を設置し、タイマーにより装置のon,offを制御しながら稼働させて、チャンバー内の二酸化塩素ガス濃度が0.05ppmvとなるように調節した(図24)。ガス濃度が安定したチャンバー内にネブライザーを用いて、菌懸濁液(約1×108~9CFU/ml)を0.2ml/minの速度で1分間噴霧し、0,30,60,90分後、インピンジャーにより浮遊菌を回収した。回収後、希釈平板法により各時間の生菌数を測定、評価を行った。コントロールとして、本発明の二酸化塩素発生装置のLEDをOFFとしたままで上記と同様の実験を行った。 (experimental method)
The chlorine dioxide generator of the present invention is placed in the center of 1 m 3 chamber, on the device by a timer, not operate while controlling the off, the chlorine dioxide gas concentration in the chamber was adjusted to be 0.05ppmv (FIG. 24). Using a nebulizer, a bacterial suspension (about 1 × 10 8 to 9 CFU / ml) is sprayed at a rate of 0.2 ml / min for 1 minute using a nebulizer in a chamber with a stable gas concentration, and 0, 30, 60, 90 After a minute, airborne bacteria were collected by an impinger. After collection, the number of viable bacteria at each time was measured and evaluated by a dilution plate method. As a control, an experiment similar to the above was performed with the LED of the chlorine dioxide generator of the present invention turned off.
1m3チャンバー内の二酸化塩素ガス濃度は二酸化塩素ガスセンサーによりモニタリングされた。二酸化塩素ガスセンサーの濃度値はイオンクロマトグラフ法により求めたガス濃度値と比較して補正された。 (Chlorine dioxide gas concentration)
Chlorine dioxide gas concentration of 1 m 3 chamber was monitored by chlorine dioxide gas sensor. The concentration value of the chlorine dioxide gas sensor was corrected in comparison with the gas concentration value obtained by ion chromatography.
装置においてLEDをOFFとしたまま実験を行ったコントロール実験の場合、生菌数は、90分で4.1×103CFU/10L airであった。一方、本発明の装置のLEDをONにして実験を行った場合、チャンバー内の二酸化塩素ガス濃度は平均0.05ppmvであり、生菌数は曝露時間90分で3.4×102CFU/10L airとなり、コントロールに対して1 log10以上(90%以上)低減した(図25)。 3. In the case of a control experiment in which the experiment was performed with the LED turned off in the experimental result apparatus, the viable cell count was 4.1 × 10 3 CFU / 10L air in 90 minutes. On the other hand, when the experiment was performed with the LED of the apparatus of the present invention turned on, the chlorine dioxide gas concentration in the chamber was an average of 0.05 ppmv, and the viable cell count was 3.4 × 10 2 CFU / at an exposure time of 90 minutes. It became 10L air, and was reduced by 1 log 10 or more (90% or more) with respect to the control (FIG. 25).
11 薬剤収納部
12 LEDチップ
13 操作基盤
14 薬剤
15 チューブ
16 開口部
20 二酸化塩素発生装置
21 二酸化塩素発生用ユニット
22 装置本体
23 エア供給口
24 ファン
25 エア排出口
30 二酸化塩素発生用ユニット
31 ガス発生口
32 薬剤収納部
33 電子基板
34 LEDチップ
35 外装部
36 エア導入口
40 二酸化塩素発生装置
41 LEDチップ装着基板
42 薬剤収納部
43 筐体部
44 送風ファン DESCRIPTION OF
Claims (14)
- 空間中の浮遊微生物を失活させる方法であって、
(1):(A)亜塩素酸塩を担持させた多孔質物質と(B)金属触媒または金属酸化物触媒とを含む、固形の薬剤を準備するステップ、
ここで、前記固形の薬剤における、前記亜塩素酸塩と前記金属触媒または金属酸化物触媒との質量比が、1:0.04~0.8である;
(2):前記固形の薬剤に、可視光を照射するステップ;および、
(3):前記固形の薬剤から発生する二酸化塩素ガスを、浮遊微生物の存在する空間へ供給するステップ;を含む、
方法。 A method of inactivating suspended microorganisms in space,
(1): (A) preparing a solid drug containing a porous material supporting chlorite and (B) a metal catalyst or a metal oxide catalyst;
Here, the mass ratio of the chlorite and the metal catalyst or metal oxide catalyst in the solid drug is 1: 0.04 to 0.8;
(2): irradiating the solid drug with visible light; and
(3): supplying chlorine dioxide gas generated from the solid drug to a space where airborne microorganisms exist;
Method. - 請求項1に記載の方法であって、
前記ステップ(3)が、「前記固形の薬剤から発生する二酸化塩素ガスを、浮遊微生物の存在する空間へ供給し、前記空間中における二酸化塩素ガス濃度を、動物は生存し得るが、前記浮遊微生物が失活する濃度とするステップ」である、
方法。 The method of claim 1, comprising:
In the step (3), the chlorine dioxide gas generated from the solid drug is supplied to the space where the floating microorganisms exist, and the concentration of the chlorine dioxide gas in the space can be survived by the animal. Is the step of setting the concentration to become inactive, "
Method. - 請求項2に記載の方法であって、
前記動物は生存し得るが、前記浮遊微生物が失活する濃度が、0.00001ppm~0.3ppmである、
方法。 The method of claim 2, comprising:
The animal can survive, but the concentration at which the airborne microorganisms are inactivated is 0.00001 ppm to 0.3 ppm,
Method. - 請求項3に記載の方法であって、
前記ステップ(3)において、前記空間中における二酸化塩素ガス濃度を0.1ppm~0.3ppmとする場合、前記二酸化塩素ガスを空間中へ供給する時間を、0.5分間~480分間とする、
方法。 The method of claim 3, comprising:
In the step (3), when the chlorine dioxide gas concentration in the space is 0.1 ppm to 0.3 ppm, the time for supplying the chlorine dioxide gas into the space is 0.5 minutes to 480 minutes.
Method. - 請求項1~4のいずれか1項に記載の方法であって、
前記浮遊微生物が、浮遊ウイルスまたは浮遊細菌である、
方法。 A method according to any one of claims 1 to 4, comprising
The floating microorganism is a floating virus or a floating bacterium,
Method. - 請求項1~5のいずれか1項に記載の方法であって、
前記ステップ(2)において照射する可視光の波長が、360nm~450nmである、
方法。 A method according to any one of claims 1 to 5, comprising
The wavelength of visible light irradiated in the step (2) is 360 nm to 450 nm.
Method. - 請求項1~6のいずれか1項に記載の方法であって、
前記金属触媒または金属酸化物触媒が、パラジウム、ルビジウム、ニッケル、チタン、および、二酸化チタンからなる群から選択される、
方法。 A method according to any one of claims 1 to 6, comprising
The metal catalyst or metal oxide catalyst is selected from the group consisting of palladium, rubidium, nickel, titanium, and titanium dioxide;
Method. - 請求項1~7のいずれか1項に記載の方法であって、
前記多孔質物質が、セピオライト、パリゴルスカイト、モンモリロナイト、シリカゲル、珪藻土、ゼオライト、および、パーライトからなる群から選択され、
前記亜塩素酸塩が、亜塩素酸ナトリウム、亜塩素酸カリウム、亜塩素酸リチウム、亜塩素酸カルシウム、および、亜塩素酸バリウムからなる群から選択される、
方法。 A method according to any one of claims 1 to 7, comprising
The porous material is selected from the group consisting of sepiolite, palygorskite, montmorillonite, silica gel, diatomaceous earth, zeolite, and perlite;
The chlorite is selected from the group consisting of sodium chlorite, potassium chlorite, lithium chlorite, calcium chlorite, and barium chlorite;
Method. - 請求項1~8のいずれか1項に記載の方法であって、
前記「亜塩素酸塩を担持させた多孔質物質」は、亜塩素酸塩を多孔質物質に含浸させ、さらに乾燥させることによって得られる、
方法。 A method according to any one of claims 1 to 8, comprising
The “porous material supporting chlorite” is obtained by impregnating porous material with chlorite and further drying.
Method. - 請求項1~9のいずれか1項に記載の方法であって、
前記多孔質物質が、さらにアルカリ剤を担持する、
方法。 A method according to any one of claims 1 to 9,
The porous material further carries an alkali agent;
Method. - 請求項10に記載の方法であって、
前記アルカリ剤が、水酸化ナトリウム、水酸化カリウム、水酸化リチウム、炭酸ナトリウム、炭酸カリウム、および、炭酸リチウムからなる群から選択される、
方法。 The method of claim 10, comprising:
The alkaline agent is selected from the group consisting of sodium hydroxide, potassium hydroxide, lithium hydroxide, sodium carbonate, potassium carbonate, and lithium carbonate;
Method. - 請求項10または11に記載の方法であって、
前記亜塩素酸塩と前記アルカリ剤とのモル比が、1:0.1~2.0である、
方法。 12. The method according to claim 10 or 11, comprising:
The molar ratio of the chlorite to the alkaline agent is 1: 0.1 to 2.0.
Method. - 請求項10~12のいずれか1項に記載の方法であって、
前記「亜塩素酸塩およびアルカリ剤を担持させた多孔質物質」は、亜塩素酸塩およびアルカリ剤を、同時または順次に、多孔質物質に含浸させ乾燥させることによって得られる、
方法。 A method according to any one of claims 10 to 12, comprising
The “porous material supporting a chlorite and an alkali agent” is obtained by impregnating a porous material with a chlorite and an alkali agent simultaneously or sequentially and drying them.
Method. - 請求項1~13のいずれか1項に記載の方法であって、
前記多孔質物質の水分含有量が10重量%以下である、
方法。 A method according to any one of claims 1 to 13, comprising
The water content of the porous material is 10% by weight or less,
Method.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017521944A JP6725153B2 (en) | 2015-06-03 | 2016-05-31 | How to inactivate suspended microorganisms in space |
KR1020177033260A KR102534711B1 (en) | 2015-06-03 | 2016-05-31 | Method for inactivating airborne microorganisms in space |
CN201680028104.0A CN107530464A (en) | 2015-06-03 | 2016-05-31 | Make the microorganism deactivated method of the floating in space |
HK18105303.1A HK1245683A1 (en) | 2015-06-03 | 2018-04-24 | Method for inactivating airborne microorganisms |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015113290 | 2015-06-03 | ||
JP2015-113290 | 2015-06-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016194884A1 true WO2016194884A1 (en) | 2016-12-08 |
Family
ID=57440464
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2016/065949 WO2016194884A1 (en) | 2015-06-03 | 2016-05-31 | Method for inactivating airborne microorganisms |
Country Status (6)
Country | Link |
---|---|
JP (1) | JP6725153B2 (en) |
KR (1) | KR102534711B1 (en) |
CN (1) | CN107530464A (en) |
HK (1) | HK1245683A1 (en) |
TW (1) | TWI754614B (en) |
WO (1) | WO2016194884A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021224673A1 (en) * | 2020-05-05 | 2021-11-11 | CO2Apps S.R.L. | Substance and method for preventing the transmission of viruses in the respiratory system |
JP7464463B2 (en) | 2019-06-28 | 2024-04-09 | 日揮触媒化成株式会社 | Chlorine Compound Adsorbent |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109701053B (en) * | 2018-12-26 | 2020-12-04 | 宁波大学 | Disinfection method |
WO2021066081A1 (en) * | 2019-10-01 | 2021-04-08 | 株式会社エースネット | Radical manufacturing method, spore sterilization method, and cancer treatment drug |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002543977A (en) * | 1999-05-18 | 2002-12-24 | サウスウエスト・リサーチ・インスティチュート | Energy activated compositions for controlled gas sustained release |
WO2007061092A1 (en) * | 2005-11-28 | 2007-05-31 | Taiko Pharmaceutical Co., Ltd. | Countermeasure against infection with floating virus |
JP2011067285A (en) * | 2009-09-24 | 2011-04-07 | Wada Kinzoku Kogyo Kk | Sterilization gas supply device |
WO2011118447A1 (en) * | 2010-03-26 | 2011-09-29 | 大幸薬品株式会社 | Device for generating chlorine dioxide |
JP2015077268A (en) * | 2013-10-17 | 2015-04-23 | シャープ株式会社 | Deodorization method |
WO2015098731A1 (en) * | 2013-12-27 | 2015-07-02 | 大幸薬品株式会社 | Composition for generating chlorine dioxide by irradiation with visible light |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005224386A (en) | 2004-02-12 | 2005-08-25 | Daiichi Seidenki Kk | Apparatus for chlorine dioxide gas sterilization |
JP5605744B2 (en) | 2010-02-25 | 2014-10-15 | ダイソー株式会社 | Stabilized chlorine dioxide agent and stable generation method of chlorine dioxide |
CN102847181B (en) * | 2012-09-26 | 2014-05-28 | 深圳万和制药有限公司 | Product capable of delaying generation and releasing of chlorine dioxide and preparation method thereof |
-
2016
- 2016-05-30 TW TW105116846A patent/TWI754614B/en active
- 2016-05-31 CN CN201680028104.0A patent/CN107530464A/en active Pending
- 2016-05-31 KR KR1020177033260A patent/KR102534711B1/en active IP Right Grant
- 2016-05-31 WO PCT/JP2016/065949 patent/WO2016194884A1/en active Application Filing
- 2016-05-31 JP JP2017521944A patent/JP6725153B2/en active Active
-
2018
- 2018-04-24 HK HK18105303.1A patent/HK1245683A1/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002543977A (en) * | 1999-05-18 | 2002-12-24 | サウスウエスト・リサーチ・インスティチュート | Energy activated compositions for controlled gas sustained release |
WO2007061092A1 (en) * | 2005-11-28 | 2007-05-31 | Taiko Pharmaceutical Co., Ltd. | Countermeasure against infection with floating virus |
JP2011067285A (en) * | 2009-09-24 | 2011-04-07 | Wada Kinzoku Kogyo Kk | Sterilization gas supply device |
WO2011118447A1 (en) * | 2010-03-26 | 2011-09-29 | 大幸薬品株式会社 | Device for generating chlorine dioxide |
JP2015077268A (en) * | 2013-10-17 | 2015-04-23 | シャープ株式会社 | Deodorization method |
WO2015098731A1 (en) * | 2013-12-27 | 2015-07-02 | 大幸薬品株式会社 | Composition for generating chlorine dioxide by irradiation with visible light |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7464463B2 (en) | 2019-06-28 | 2024-04-09 | 日揮触媒化成株式会社 | Chlorine Compound Adsorbent |
WO2021224673A1 (en) * | 2020-05-05 | 2021-11-11 | CO2Apps S.R.L. | Substance and method for preventing the transmission of viruses in the respiratory system |
Also Published As
Publication number | Publication date |
---|---|
CN107530464A (en) | 2018-01-02 |
KR102534711B1 (en) | 2023-05-19 |
JPWO2016194884A1 (en) | 2018-04-05 |
HK1245683A1 (en) | 2018-08-31 |
JP6725153B2 (en) | 2020-07-15 |
TWI754614B (en) | 2022-02-11 |
TW201701906A (en) | 2017-01-16 |
KR20180015624A (en) | 2018-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210364171A1 (en) | Air treatment systems | |
US11103611B2 (en) | Method and device for enhancing the reduction of pathogens, allergens and odor-causing agents | |
CN108025182B (en) | Method and device for disinfection, sterilization and disinfection | |
EP2051743B1 (en) | Method for using ozone as a disinfectant | |
WO2016194884A1 (en) | Method for inactivating airborne microorganisms | |
US20080194009A1 (en) | Novel HVAC pathogen neutralization system | |
US20230301307A1 (en) | Systems, methods, and apparatuses for disinfection and decontamination | |
JP2019187653A (en) | Sterilization disinfection apparatus and method | |
Giampieri et al. | An overview of solutions for airborne viral transmission reduction related to HVAC systems including liquid desiccant air-scrubbing | |
US20240033386A1 (en) | A disinfection system, method and chamber thereof | |
JP6990963B2 (en) | Ozone gas disinfectant | |
KR102265975B1 (en) | Smart led prevention system | |
RU2532174C1 (en) | Method of purifying air mixture in surgery and maternity blocks from pathogenic microflora, highly volatile organic and carcinogenic substances and recovering oxygen in closed rooms | |
WO2022024071A1 (en) | Apparatus and methods for decontaminating air supply in enclosed spaces | |
CN218608816U (en) | Ultraviolet ray and photocatalyst combined multiple disinfection, sterilization and odor removal structure | |
JP2020146471A (en) | Ozone gas sterilizer | |
US20240066175A1 (en) | Hydroxyl ion generator apparatuses for ceiling mount or walk through | |
Shambhavi et al. | BT100, a three-in-one, multipurpose disinfecting, deodorizing, and air-cleaning solution with an effective, gradual, and continuous gaseous chlorine dioxide-releasing substance | |
US9078940B2 (en) | Infrared radiation filter systems, methods of use and methods of disinfection and decontamination | |
EP4351664A1 (en) | Systems, methods, and apparatuses for disinfection and decontamination | |
Scarlett | The Role of Active Air Disinfection in Mitigating the Effects of Aerosol Generating Dental Procedures | |
Ereth et al. | Disinfection of Viruses and Bacteria with Modulated Dielectric Barrier Discharge, Bipolar Ionization, Photocatalytic Oxidation, and Ultraviolet-C Light | |
Giampieri et al. | Publisher's copyright statement: Additional information |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16803319 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017521944 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20177033260 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16803319 Country of ref document: EP Kind code of ref document: A1 |